White paper ‘Future of Children’s Mental Health’ makes a case for accelerating digital therapeutics’ integration.
- BfB Labs white paper spotlights the intensifying crisis in children and young people’s mental healthcare and outlines the case for accelerating digital interventions’ integration.
- White paper maps a new care pathway integrating digital solutions into young people’s mental healthcare.
- 4 out of 10 (36.36 percent) of Child and Adolescent Mental Health Services (CAMHS) have not adopted any new digital mental health supports for children and young people (CYP) since the onset of COVID-19.
LONDON, October 22, 2020. A new white paper ‘Future of Children’s Mental Healthcare BfB Labs White Paper , which has been published today, spotlights the intensifying crisis and outlines why widespread adoption of digital therapeutics is hindered by a lack of digital literacy, making it difficult for commissioners to evaluate new interventions.
Published by BfB Labs, a pioneering UK company using emergent technology to tackle the status quo in children’s mental healthcare to ensure equitable access to early interventions that improve lifelong outcomes for children.
“The pandemic demands an imperative to make digital mental health therapeutics a routine part of early access and early intervention,” said Manjul Rathee, CEO of BfB Labs. “Even when a digital therapeutic has been approved by the Medicines Healthcare Regulatory Authority (MHRA), is CE marked, has demonstrated high levels of safety, efficacy, and has good economic data, this still does not guarantee widespread adoption. Multiple barriers remain, including an organization’s attitude to risk, and difficulties identifying and evaluating interventions.”
BfB Labs whitepaper provides intelligence on the current status quo and paints a clear picture of the roadblocks and also maps where forward-thinking CAMHS organizations can integrate digital therapeutics into children and young people’s mental healthcare pathways to meet surging demand for help effectively.
“According to Manjul Rathee, “Meeting the scale of support required demands moving beyond rhetoric to upskilling and evolving services to meet young people where they are today – on their mobile or tablet.”
BfB Labs recently announced it had received regulatory approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Lumi Nova – the first mobile game for pediatric anxiety disorders that provides ongoing evidence.
About BfB Labs
- Founded in 2015, BfB Labs has pioneered video game-based digital therapies for children using proven cognitive-behavioral therapy (CBT) techniques to improve emotional regulation and resilience and now anxiety disorders.
- BfB Labs is committed to building future mental healthcare for children today with evidence-based interventions that are accessible and affordable and treat conditions in an entirely new and engaging way. During this time of urgent need for digital mental health solutions that can respond to soaring demand, BfB labs help to enable NHS Integrated Care Systems, and Clinical Commissioning Groups, schools, to provide MHRA approved, safe, flexible, and cost-effective solutions.
- BfB Labs combine scientific and clinical rigor with the ingenuity of emergent technology and games to democratize access to evidence-based children’s mental health interventions.
- Lumi Nova has been funded by NHS England and NHS Improvement’s SBRI Healthcare program.
- Driven by BfB Labs’ belief that effective interventions should be co-created with users, the people that care for them, and should also be highly engaging and clinically effective.
- BfB Labs treatments are delivered through an immersive mobile game experience to drive user engagement and compliance.
- BfB Lab’s flagship products include Lumi Nova and Champions of the Shengha, a heart-rate driven biofeedback mobile game that improves emotional self-regulation and resilience skills. Both digital therapeutics meet the highest standards in clinical safety & data security and are both CE marked and approved by the Medicines and Healthcare Products Regulatory Agency (MHRA).